ZEVONTABART VEDOTIN
UNII YWR7S7Z695

Substance Identification & Data

This profile provides standardized clinical and technical data for Zevontabart Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) YWR7S7Z695.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3060218-91-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

YWR7S7Z695

CAS Registry Number

3060218-91-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ZEVONTABART VEDOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

13957

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Zevontabart Vedotin

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Zevontabart Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Zevontabart Vedotin

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-442) [VH (Homo sapiens IGHV1-2*06 (88.8%) -(IGHD) -IGHJ6*01 (85.7%), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115) -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, 14-G1v96-1 hinge C7, del8, del10 (CH1 R120 (212) (116-213), hinge 1-7,9,11-15 K>C (220), T8>del, T10>del (214-226), CH2 (227-336), CH3 E12 (352), M14 (354) (337-441), CHS K2>del (442))(116-442)], (218-215')-disulfide with L-kappa light chain humanized (1'-215') [V-KAPPA (Homo sapiens IGKV1-39*01 (83.3%) -IGKJ4*01 (100%), CDR-IMGT [7.3.9] (27'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (99.1%) Km3 A45.1, V101, 16-KCv93-1 C117 (C-KAPPA A45.1 (154'), V101 (192'), V117>C (206')) (109'-215')]; dimer (220-220'':222-222'':225-225'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of the engineered L-cysteinyl C117 of the C-kappa domain (206', 206''') with (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin) groups

Immunoglobulin G1 [220-cysteine,de-C-terminal lysine], anti-(human hepatocyte growth factor receptor c-Met) (human-Mus musculus monoclonal Q397 γ1-chain), disulfide with [206′′-cysteine] human-Mus musculus monoclonal Q397 κ-chain, dimer, 206′′,206′′′-bis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N<sup>5</sup>-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody, conjugated at the engineered cysteinyl C117 of the two light chain C-kappa domains to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE) (zevontabart vedotin)

zevontabart vedotin [INN]

External Clinical & Regulatory Resources

Previous UNIIYWR673H4SE

Next UNIIYWT7AJ7O7P